Beam Therapeutics Inc. (BEAM) bonds
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$100.26M
Long-term debt
Net debt
-$119.57M
After $219.83M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
Individual notes, bonds and loans
Beam Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
See a number that looks wrong?